The abuse of the designer amphetamines such as 3,4-methylenedioxymethamphetamine (MDMA) is increasing throughout the world. They have become popular drugs at all night techno dance parties, and their detection is an important issue. The objective of the presented study was to identify an unknown compound detected by thin-layer chromatography (TLC) in the urine of an illicit drug abuser. The compound was isolated by TLC and analyzed by gas chromatography-mass spectrometry (GC-MS) in electron ionization (El) and positive ion chemical ionization (PICI) mode to elucidate its chemical structure. Based on El-MS and PICI-MS mass spectral data, the unknown compound was indicated to be a structure similar to MDMA, substituted by a single chlorine atom--a chlorinated MDMA (CI-MDMA). To confirm the CI-MDMA structure, the unknown compound was silylated, trifluoroacetylated, acetylated, heptafluorobutyrylated, and analyzed by GC-MS. The position of the chlorine atom cannot be assigned exactly from the mass spectral data presented here; however, we believe that the unknown compound could be 6-CI-MDMA.
Introduction
The current wave of popularity of recreational "rave drugs" among young teenagers has spread around the world. These drugs are produced in illicit laboratories and sold illegally in drug market. The most popular has become 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy), an amphetamine derivative, for its entactogenic and empathogenic effects. The majority of published papers on designer drugs address the pharmacologic effects and metabolism of MDMA . Experimental studies, both animal and human, as well as human epidemiologic data and individual case reports indicate significant health and social risks connected with the abuse of MDMA. Serotonin syndrome, hepatotoxicity, neurotoxicity, psychopathology, and life-threatening effects have been associated with the use of MDMA. There are hundreds of possible modifications to the basic amphetamine structure that retain * Author to whom correspondence should be addressed.
Aim
The aim of the presented study was to identify an unknown compound detected by thin-layer chromatography (TLC) in the urine of an illicit drug abuser. The compound was isolated by TLC and analyzed by gas chromatography-mass spectrometry (GC-MS) in electron ionization (EI) and positive ion chemical ionization (PICI) mode to elucidate its chemical structure.
Case History
At a party, a 29-year-old male ingested cocaine, marijuana, four Ecstasy pills, and alcoholic drinks. The following day, at about 6:00 in the morning, he was transported by his friends to the hospital. He was unconscious and hypoxical. A short time later, bradycardia developed, and he was hypoventilated. The patient was intubated and received intravenous fluids. Two hours after regaining consciousness, he was extubated, and at about 6:00 in the afternoon on the same day, he was discharged from the hospital. A urine specimen collected from him in the hospital yielded positive EMIT immunoassay screenings for cannabinoids, amphetamines, and cocaine. Instrument Du Pont aca IV, Medical Products (Wilmington, DE) was used. A routine analysis of urine by TLC using a fractional diethyl ether liquid-liquid extraction identified ephedrine, MDMA, and an unknown compound.
Methods

Materials
The TLC glass plate (Kieselgel G 60 10 x 20 cm) was produced by Merck (Darmstadt, Germany). The following standards were obtained from UNDCP (Vienna, Austria): atropine sulfate, codeine phosphate, phenmetrazine hydrochloride, aminophenazone, diazepam, amphetamine sulfate, methamphetamine hydrochloride, mephentermine sulfate, phentermine hydrochloride, ephedrine hydrochloride, norephedrine hydrochloride, and MDMA hydrochloride. N-Methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) and N-methyl-bis-trifluoroacetamide (MBTFA) were obtained from MachereyNagel, (D~ren, Germany). Heptafluorobutyric anhydride (HFAA), acetic anhydride (ACA), and stabilizer ],2-ethanedithiobis(trimethylsilane) (EDTBTS) were obtained from Fluka (Buchs, Switzerland). Support chemicals such as hydrochloric acid, tartaric acid, sodium carbonate, sodium phosphate, and evaporated to dryness. The aqueous phase was extracted with 100 mL diethylether again after adding 5 g solid sodium carbonate to adjust the pH to 9.0. The organic phase (basic urine extract) was transferred to a dish and, after adding 50 pL of concentrated hydrochloric acid, evaporated to dryness. Reconstituted basic urine extract (50 pL), 10 pL of 1 mg/mL drug standards for identifying unknown compounds (AKFADatropine sulfate, codeine phosphate, phenmetrazine hydrochloride, aminophenazone, and diazepam), and 10 pL MDMA standard (1 mg/mL in ethanol) were spotted on a TLC plate, eluted in ethyl acetate/ethanol/ammonia (36:2:2, v/v/v), and detected with Dragendorff, Marquis, and Fast Black K color reagents. Ten microliters of amphetamines standard (amphetamine, methamphetamine, mephentermine, phentermine, ephedrine, norephedrine, and MDMA) and 50 pL of the basic urine extract were spotted on a TLC plate and eluted in benzene/methanol/isopropanol/ammonia (35:5: and ammonium iodide were obtained from Lachema (Brno, Czech Republic). Ethylacetate and cyclohexane were obtained from Scharlau (Barcelona, Spain), and methanol was obtained from Penta (Chrudim, Czech Republic). All chemicals were of analytical grade unless otherwise stated.
TLC
Glass TLC plates (Kieselgel G 60 10 x 20 cm) were used with a mobile phase of ethyl acetate/ethanol/ammonia (36:2:2 v/v/v). A sample of urine was prepared by fractional diethylether liquid-liquid extraction. Fifty milliliters of urine was extracted with 100 mL diethylether after 50 pL of concentrated hydrochloric acid was added. The organic phase (acidic urine extract) was transferred to a dish 
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? N'oH, and held 4 min. Helium was the carrier gas at a constant flow rate of 1.0 mL/min. Injections of 1 IJL were made in splitless mode with a splitless time of 1.0 min and an injector temperature of 250~ The transfer line temperature was 280~ Scan time was 1.0 s. Full scan spectra were obtained in EI mode, recording mass-to-charge ratios from 50 to 500. 
and held 10 rain. Helium was used as the carrier gas at a constant flow rate of 1.0 mL/min. The injections were made in septum-equipment programmable injector (SPI) mode with a temperature program from 85~ to 230~ The injection volume was 1.0 IJL. The transfer line temperature was 280~ and the scan time was 0.5 s. Full scan spectra were obtained in EI mode or in the PICI mode, recording mass-to-charge ratios from 35 to 500. Ionization gas was methanol vapor.
Derivatizati0n
The unknown compound band from TLC plate was scraped and extracted with I mL methanol. The extract was divided to five aliquots and evaporated before derivatization.
For TMS derivatization (trimethylsilylation), the extract was derivatized with 50 t~L MSTFA/ammonium iodide (NH4I)/ 1,2-ethanedithiobis (trimethylsilane) (1000:2.5:3, v/w/v) at 70~ for 20 min. This reagent mixture is routinely used in doping control. After cooling to laboratory temperature, the mixture was transferred to a new vial and injected into the GC-MS column. For TFA derivatization (trifluoroacetylation), the extract was derivatized with 50 ]JL MBTFA at 70~ for 30 rain (39). After cooling, the mixture was transferred to a new vial and injected into the GC-MS column.
ACA derivatization (acetylation) was achieved by mixing the extract with 50 IlL of ACA/pyridine 10:1 (v/v) at 60~ for 30 min. This was followed by the addition of 10 IJL of 0.01% tartaric acid in ethyl acetate (18) (19) (20) (21) . The vial was removed from the heating block, allowed to cool to laboratory temperature, and evaporated to dryness. The residue was reconstituted in 100 IJL ethyl acetate and injected into the GC-MS column.
For HFB derivatization (heptafluorobutyrylation), the extract was derivatized with 50 IJL HFAA at 70~ for 30 min. After cooling, redistilled cyclohexane (100 IlL) and an aqueous 0.5 mol/L sodium phosphate solution (200 IlL) were added (22) . The vial was vortex mixed, and the top phase was transferred to a new vial before injection into the GC-MS column.
Results and Discussion
TLC
The calculated Rr value for the MDMA standard (Rf = 0.39) corresponded to one of the separated bands of the basic urine extract. The Rf value of the unknown compound was calculated to be 0.52 and did not allow for identification of the compound. The unknown compound band from each plate was scraped and extracted with methanol for subsequent derivatization prior to GC-MS studies.
GC-MS
GC-MS analyses of an unknown compound were performed using two instruments. The compound of interest was analyzed alone (Figure 1 ) and after derivatizations with MSTFA ( Figure  2 ) and MBTFA (Figure 3 ) on instrument I (Hewlett-Packard) with El and after derivatizations with ACA ( Figure 4 ) and HFAA ( Figure 5 ) on instrument 2 (Finnigan MAT Magnum) with electron ionization. To determine the molecular weight of the unknown compound, instrument 2 was used with positive ion chemical ionization (Figure 6 ).
The EI-MS spectrum of MDMA contains the following ions: rn/z 193, 177, 135, 77, and 58 (40) . Closer scrutiny of the EI-MS and PICI-MS mass spectral data of the unknown compound indicated a structure similar to MDMA, with the substitution of The position of the chlorine atom cannot be exactly determined from the mass spectral information presented here; however, we believe that the unknown compound could be 6-CI-MDMA. Position 2 and 5 would also be possible, but 6-CI-MDMA has been listed as a new synthetic drug in Europe and in the USA since the mid*1990s (41) making it the most likely candidate. Our assumption can be supported by a paper published by Lewis and co-workers (42), in which 6-CI-MDMA has been identified in an illicit drug seizure, which included 26 off-white tablets. 6-C1-MDMA has been identified by GC-MS using El after derivatization with heptafluorobutyric anhydride and 1H-NMR spectroscopy. In our case, we isolated the unknown compound from a biological matrix and did not have enough material for a 1H-NMR study. 
Conclusions
A chlorinated MDMA was identified after derivatization of an unknown compound that had been isolated by TLC. Using a literature source (42) , and through interpretation of our mass spectra of heptafluorobutyrylated CI-MDMA, it was possible to surmise that the unknown compound could be 6-Cl-MDMA. To support this claim, we used additional derivatization techniques such as acetylation, trifluoroacetylation, and silylation. For unambiguous proof that the compound is 6-CI-MDMA, synthesis and analysis of all three possible structure should be done in future research. 6-C1-MDMA is listed in New Synthetic Drugs reported in Europe and the U.S. since the mid-1990s in the joint action of The European Monitoring Centre for Drugs and Drug Addiction (41).
